Theralase Technologies Inc. V.TLT

Project Frontrunner

[N0taP00p]

Based on this overview, TLT seems to check all the boxes for being a candidate. What I can't tell is if the drug sponsor (TLT) has to start a phase 1 trial again. It does feel like that based on the wording ie. Design the trial with intent to seek approval in an earlier setting of the targeted application.  That's not how the current NMIBC trial is designed (starting point is after failing BCG).  But even getting considered for this would be a huge boost given the safety profile and efficacy so far.  In the meantime, we wait for any news.  To BTD and beyond. 

https://www.fda.gov/about-fda/oncology-center-excellence/project-frontrunner

 

[ScienceFirst]

I already documented this, just like project Orbis. Frontrunner would allow TLT to offer its treatment in early-stage settings, which would instantly widen our market opportunity and allow us to displace BCG much faster.  BCG market is a 17.5B$ market.

[ScienceFirst]

From the standpoint of patients, Project FrontRunner can offer new, potentially effective treatments to a much larger patient population earlier

[N0taP00p]

I'm giving you all my reputation points (zero) for already having documented it before, whether you did or not. We need to keep you happy and posting. Better than watching paint dry. Give us your thoughts on why the makers of Photofrin shouldn't be salivating over TLT now.  Haven't seen that addressed by anyone.